Compare DFLI & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | EVAX |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 42.7M |
| IPO Year | N/A | 2021 |
| Metric | DFLI | EVAX |
|---|---|---|
| Price | $3.97 | $4.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $22.50 | $12.33 |
| AVG Volume (30 Days) | ★ 851.1K | 70.4K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,783,000.00 | $7,650,000.00 |
| Revenue This Year | $17.85 | $128.77 |
| Revenue Next Year | $30.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.24 | ★ 132.17 |
| 52 Week Low | $1.50 | $1.20 |
| 52 Week High | $26.50 | $12.15 |
| Indicator | DFLI | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 61.74 | 36.46 |
| Support Level | $3.75 | $4.11 |
| Resistance Level | $4.55 | $4.85 |
| Average True Range (ATR) | 0.45 | 0.38 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 63.14 | 9.49 |
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.